## Xiaodong Jiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8269770/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 71.	8.6	103
2	Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis. Targeted Oncology, 2016, 11, 501-505.	3.6	44
3	A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e443-e449.	2.3	35
4	The role and significance of VEGFR2 <sup>+</sup> regulatory T cells in tumor immunity. OncoTargets and Therapy, 2017, Volume 10, 4315-4319.	2.0	32
5	Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 669-77.	2.2	25
6	The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment. Biomedicine and Pharmacotherapy, 2017, 88, 134-137.	5.6	19
7	Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. Cancer Immunology, Immunotherapy, 2019, 68, 1467-1477.	4.2	19
8	The SUMO-specific protease family regulates cancer cell radiosensitivity. Biomedicine and Pharmacotherapy, 2019, 109, 66-70.	5.6	14
9	Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1329-1337.	2.5	13
10	<p>Effects of combined inhibition of STAT3 and VEGFR2 pathways on the radiosensitivity of non-small-cell lung cancer cells</p> . OncoTargets and Therapy, 2019, Volume 12, 933-944.	2.0	11
11	Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2020, 131, 110557.	5.6	7
12	SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signaling pathway in non-small cell lung cancer. Anti-Cancer Drugs, 2020, 31, 492-499.	1.4	7
13	The significance of SUMOylation of angiogenic factors in cancer progression. Cancer Biology and Therapy, 2019, 20, 130-137.	3.4	3
14	Safety and efficacy of PD-1 blockade-activated multiple antigen specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials Journal of Clinical Oncology, 2019, 37, e14014-e14014.	1.6	1